Patents of Pentoxifylline Administration on Some Diseases and Chronic Wounds
Mohammad Bayat, Abdollah Amini, Fatemesadat Rezaie and Shiva Bayat
Affiliation: Cellular and Molecular Biology Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Zip code: 1985717443, Iran, Po Box: 19395/4719.
Keywords: Pentoxifylline, peyronie’s disease, ulcer, vascular occlusive disease, wound, wound healing.
Each year in the United States alone, for about 50 million surgeries is undertaken. An extra 50 million traumatic
wounds increased further the burden of morbidity stemming from acute wounds. For instance, chronic ulcers are a growing
cause of significant patient morbidity and mortality. Pentoxifylline, a xanthine derivative, is a non-selective phosphodiesterase
inhibitor that raises intracellular cyclic adenosine monophosphate. Pentoxifylline has been used clinically to treat
vascular diseases and some types of chronic wounds. The purpose of this paper is to provide an overview on all available
patents regarding pentoxifylline administration for abnormal wound healing and chronic wounds. All available published
patents regarding to effect of pentoxifylline on abnormal wound healing and ulcers were studied. These patents reveal that
pentoxifylline administration has an important additional effect in the treatment of different diseases such as fibrosis, Peyronie’s
disease, venous leg ulcers, circulatory disorders, vascular occlusive wounds and diabetic ulcer wounds.
Rights & PermissionsPrintExport